BioLineRx (BLRX) Announces Publication of Positive BL-5010 Phase 1/2 Data in BJD
Tweet Send to a Friend
BioLineRx (NASDAQ: BLRX) announced the publication of positive results from the Phase 1/2 clinical trial of BL-5010, a novel formulation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
